Dr. Yasodha Natkunam, MD, PHD
Pleasanton, CA
24 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Natkunam, Anatomic Pathologist & Clinical Pathologist in Pleasanton, CA?
Dr. Yasodha Natkunam, MD, PHD is an Anatomic Pathologist & Clinical Pathologist, who primarily practices in Pleasanton, CA with 1 additional practice location. She has been practicing for over 24 years and is board certified. Dr. Natkunam graduated from Icahn School of Medicine at Mount Sinai and completed her residency at Stanford University Program. Dr. Natkunam is fluent in English and Tamil, and is currently seeing new patients. Dr. Natkunam’s practice accepts Kaiser Permanente, Medicaid, Medicare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Natkunam’s office at (650) 723-7211.
Where did Dr. Natkunam go to medical school and complete their residency?
Residency: Stanford University Program
Medical School: Icahn School of Medicine at Mount Sinai
Is Dr. Natkunam board certified as an Anatomic Pathologist & Clinical Pathologist?
Yes, Dr. Yasodha Natkunam, MD, PHD is board certified by the American Board of Pathology since 1998
What languages does Dr. Natkunam speak?
Dr. Natkunam and their clinical team can communicate with patients in the following languages:
English
Tamil
What conditions does an Anatomic Pathologist & Clinical Pathologist like Dr. Natkunam typically treat?
As an Anatomic Pathologist & Clinical Pathologist, Dr. Natkunam diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Natkunam. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Multiple Myeloma
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)
- Active multiple myeloma
- Untreated multiple myeloma
- Plasma cell myeloma
ICD-10 Codes:
- C9000: Multiple myeloma not having achieved remission
Also known as:
- Diffuse Large B-cell Lymphoma
- Lymphoma
- DLBCL
- Aggressive B-cell Lymphoma
- Diffuse B-cell Lymphoma
ICD-10 Codes:
- C8330: Diffuse large B-cell lymphoma, unspecified site
- C8339: Diffuse large B-cell lymphoma, extranodal and solid organ sites
- C83398: Diffuse large B-cell lymphoma of other extranodal and solid organ sites
Also known as:
- Localized Swollen Lymph Nodes
- Widespread Swollen Lymph Nodes
- Enlarged glands in one area
- Local lymphadenopathy
- Swollen glands
- Generalized lymphadenopathy
- Multiple swollen glands
- Body-wide enlarged lymph nodes
ICD-10 Codes:
- R590: Localized enlarged lymph nodes
- R591: Generalized enlarged lymph nodes
Also known as:
- Acute Myeloid Leukemia
- AML Leukemia
- Acute Myeloblastic Leukemia
- Acute Myelogenous Leukemia
ICD-10 Codes:
- C9200: Acute myeloblastic leukemia, not having achieved remission
Also known as:
- Myelodysplastic Syndrome
- Myelodysplastic Syndromes
- Myelodysplastic Syndromes Treatment (PDQ®)
- MDS
- Preleukemia
- Bone marrow failure disorder
ICD-10 Codes:
- D469: Myelodysplastic syndrome, unspecified
What procedures does an Anatomic Pathologist & Clinical Pathologist like Dr. Natkunam typically perform?
As an Anatomic Pathologist & Clinical Pathologist, procedures performed by Dr. Yasodha Natkunam may include:
- Ancillary Testing
- Blood Sample
- Blood Smear
- Blood Sugar / Plasma Glucose Test
- Bone Pathology
- Chemical Pathology Consultation
- Chemical Pathology Follow Up
- Electrolyte Test / PH Imbalance
Please contact Dr. Natkunam's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. Natkunam accept my insurance?
Dr. Natkunam accepts most major insurance plans. Important: Please call our office at (650) 723-7211 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Natkunam accept in Pleasanton, CA?
Dr. Natkunam in Pleasanton, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
AllCare Health
Blue Shield of California
Cigna Group
CVS Health (formerly Aetna)
Kaiser Permanente
Medicaid
Medicare
Molina Healthcare
State of California
UnitedHealth Group
View All Insurances
Where is Dr. Natkunam's office located?
Dr. Yasodha Natkunam's Primary Practice
5555 W Las Positas Blvd
Pleasanton, CA 94588
(650) 723-7211
What hospitals are Dr. Natkunam affiliated with?
Castle Connolly Top Hospital
This doctor is affiliated with a Castle Connolly Top Hospital.
Dr. Natkunam has admitting privileges at the following hospitals:
Stanford Health Care - Stanford Hospital,Stanford, CA
Ranked in 6 Procedures
Ranked in 6 Procedures
Stanford Health Care - Valleycare,Pleasanton, CARanked in 2 Procedures
Ranked in 2 Procedures
Alta Bates Summit Medical Center - Summit Campus,Oakland, CA
Ranked in 2 Specialties
Ranked in 4 Procedures
Ranked in 2 Specialties
Ranked in 4 Procedures
Ucsf Medical Center At Parnassus,San Francisco, CARanked in 2 Procedures
Ranked in 2 Procedures
Community Hospital Of Monterey Peninsula,Monterey, CARanked in 2 Procedures
Ranked in 2 Procedures
Kaiser Permanente Oakland Medical Center,Oakland, CARanked in 3 Procedures
Ranked in 3 Procedures
Recognitions
Publications
Germil centre protein HGAL promotes lymphoid hyperplasia
, 2013
Bevacizumab and cyclosphosphamide, doxorubicin
, 2014
Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte
, 2014
LMO2 (LIM domain only 2) is expressed in a subset of acute myeloid leukaemia and correlates with
, 2014
Expression of the Activating Receptor, NKp46 (CD335), in Human tural Killer and T-Cell Neoplasia.
, 2013
Molecular and genomic aberrations in Chlamydophila psittaci negative ocular adnexal margil zone
, 2013
LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas
, 2013
CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma
, 2013
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades
, 2013
Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma
, 2013
Usefulness of HGAL and LMO2 Immunohistochemistry in the Identification of Follicular Lymphomas of
, 2013
Indolent T-Lymphoblastic Proliferation (iT-LBP)
, 2013
The spectrum of lymphoblastic, nodal and extranodal T-cell lymphomas
, 2013
Syk-Induced Phosphatidylinositol
, 2013
Integration of Genomic Medicine into Pathology Residency Training The Stanford Open Curriculum
, 2013
Selective Immunophenotyping for Diagnosis of B-cell Neoplasms
, 2013
CD137 Ligand Is Expressed in Primary and Secondary Lymphoid Follicles and in B
, 2013
FHIT, EGFR, and MSH2
Follicular lymphoma in young adults: a clinicopathological and molecular study of 200 patients.
TdT(+) T-lymphoblastic Populations Are Increased in Castleman Disease
, 2012
The contribution of HGAL
, 2012
Cyclin D3 coordites the cell cycle during differentiation to regulate erythrocyte size and number
, 2012
CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T
, 2012
Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma
, 2012
LIM domain only 2 protein expression, LMO2 germline genetic variation
, 2012
IgG4-Related Systemic Sclerosing Disease of the Ocular Adnexa A Potential Mimic of Ocular Lymphoma
, 2012
The spectrum of B-cell lymphoma, unclassifiable
, 2012
Aggressive EBV-associated Lymphoproliferative Disorder
, 2012
Expression of the CD2AP adaptor molecule in normal, reactive and neoplastic human tissue.
, 2012
Lack of association of tumor
, 2012
Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population
, 2011
Prediction of survival in diffuse large B
, 2011
Clinicopathologic and Molecular Features of 122 Brazilian Cases of Nodal and Extranodal NK
, 2011
MicroRs Are Independent Predictors of Outcome in Diffuse Large B
, 2011
LMO2 protein expression predicts survival in patients with rheumatoid arthritis
, 2011
HGAL Protein Expression Persists
, 2011
The Efficacy of HGAL and LMO2 in the Separation of Lymphom
, 2011
T-cell lymphomas: a tale of heterogeneity masking clarity
, 2011
Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte
, 2010
Oral and Extraoral Plasmablastic Lymphoma Similarities and Differences
, 2010
Immunoarchitectural Patterns in Follicular Lymphoma
, 2010
Expression of LMO2 Is Associated With t(14;18)
, 2010
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma
, 2010
Embryonic Stem Cell-Derived Endothelial Cells Engraft Into the Ischemic Hindlimb
, 2010
C-C Chemokine Receptor 1 Expression in Human Hematolymphoid Neoplasia
, 2010
The inducible T-cell co-stimulator molecule is expressed on subsets of T cells
, 2010
Characterization of D-cyclin proteins in hematolymphoid neoplasms
, 2010
PD-1 Expression in T-cell Lymphomas and Reactive Lymphoid Entities
, 2010
CD81 protein is expressed at high levels in normal germil center B cells
, 2010
Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival
, 2010
Building tissue microarrays from suspension cells.
, 2010
Microtubule-associated Protein-2 is a Sensitive Marker of Primary and Metastatic Neuroblastoma
, 2009
Extracellular Sigl-Regulated Kise Positively Regulates the Oncogenic Activity of MCT
, 2009
Characterization of c
, 2009
Immunoarchitectural Patterns in Nodal Margil Zone B-Cell Lymphoma A Study of 51 Cases
, 2009
nofluidic proteomic assay for serial alysis of oncoprotein activation in clinical specimens
, 2009
Low Stage Follicular Lymphoma
, 2009
Lack of Utility of CD20 Immunohistochemistry in Staging Bone Marrow Biopsies for Diffuse Large B
, 2009
The Transcription Factor LMO2 Is a Robust Marker of Vascular Endothelium and Vascular Neoplasms
, 2009
Gray zones around diffuse large B cell lymphoma
, 2009
Human germil center-associated lymphoma protein expression is associated with improved failure
, 2009
PTP1B is a negative regulator of interleukin 4-induced STAT6 sigling
, 2008
Immunohistochemical characterization of sal-type extranodal NK
, 2008
Tissue microarrays from bone marrow aspirates for high
, 2008
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with
, 2008
Expression of HGAL in primary cutaneous large B-cell lymphomas
, 2008
Expression of the human germil-centre
, 2008
LMO2 protein expression predicts survival in patients with diffuse large B
, 2008
Prognostic significance of VEGF, VEGF receptors
, 2008
The Stanford Tissue Microarray Database
, 2008
Selective loss of B-cell phenotype in lymphocyte predomint Hodgkin lymphoma
, 2007
The utility of PAX5 immunohistochemistry in the diagnosis of undifferentiated malignt neoplasms
, 2007
Intertiol standardized approach for flow cytometric residual disease monitoring in chronic
, 2007
Oncogenic regulators and substrates of the aphase promoting complex
, 2007
Mast cell tryptase and microphthalmia transcription factor effectively discrimite cutaneous mast
, 2007
Microvessel density and expression of vascular endothelial growth factor and its receptors
, 2007
The oncoprotein LMO2 is expressed in normal germil-center B cells and in human B-cell lymphomas
, 2007
Expression of the R-binding protein VICKZ in normal hematopoietic tissues and neoplasms
, 2007
Expression of the human germil center-associated lymphoma
, 2007
The biology of the germil center.
, 2007
Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease
, 2006
EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis
, 2006
Jaw I/LRMP, a germil centre-associated marker for the immunohistological study of B-cell lymphomas
, 2006
Prognostic immunohistologic markers in human tumors: why are so few used in clinical practice?
, 2006
The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas
, 2006
CD10 expression in peripheral T-cell lymphomas complicated by a proliferation of large B-cells
, 2006
Loss of CD19 expression in B-cell neoplasms
, 2006
Transmembrane adaptor molecules: a new category of lymphoid-cell markers
, 2006
Utility of syndecan-1
, 2005
Follicular dendritic cell immunohistochemical markers in angioimmunoblastic T-cell lymphoma
, 2005
TMA-combiner, a simple software tool to permit alysis of replicate cores on tissue microarrays
, 2005
Cytologic diagnosis of Burkitt lymphoma.
, 2005
Treatment of verruca vulgaris with topical cidofovir in an immunlocompromised patient
, 2005
Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine
, 2005
Expression of the human germil center-associated lymphoma (HGAL) protein
, 2005
Expression pattern of intracellular leukocyte
, 2005
Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas
, 2005
Expression of the bcl-6 and MUM1
, 2005
A novel method for making tissue microarrays from small numbers of suspension cells
, 2005
The NFATc1 transcription factor is widely expressed in white cells
, 2005
Expression pattern of FCRL (FREB, FcRX) in normal and neoplastic human B cells
, 2004
Immunophenotypic and genotypic characterization of progression in follicular lymphomas
, 2004
Intracellular siglling molecules as immunohistochemical markers of normal
, 2004
Atypical cellular disorders.
, 2004
Characterization of variant patterns of nodular lymphocyte predomint Hodgkin lymphoma with
, 2003
Plasmablastic lymphoma presenting in a human immunodeficiency virus-negative patient: a case report
, 2003
Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100
What is Dr. Natkunam's NPI number?A National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Natkunam's National Provider Identifier (NPI) number is 1033261151.
What common questions do patients ask about Dr. Natkunam?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Natkunam
What is Dr. Yasodha Natkunam's specialty?
Dr. Natkunam is an Anatomic Pathologist & Clinical Pathologist near Pleasanton, CA.
What does an Anatomic Pathologist & Clinical Pathologist do?
A pathologist focuses on the causes and nature of diseases, contributing to diagnosis, prognosis, and treatment by applying knowledge from biological, chemical, and physical sciences in the laboratory. They utilize microscopic examinations of tissue specimens, cells, and body fluids, along with clinical laboratory tests on fluids and secretions, to diagnose, exclude, or monitor diseases.
Is Dr. Yasodha Natkunam affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Natkunam is affiliated with Stanford Health Care - Stanford Hospital, Stanford Health Care - Valleycare, Alta Bates Summit Medical Center - Summit Campus, Ucsf Medical Center At Parnassus, Community Hospital Of Monterey Peninsula, Kaiser Permanente Oakland Medical Center which are a Castle Connolly Top Hospitals. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see an Anatomic Pathologist & Clinical Pathologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see an Anatomic Pathologist & Clinical Pathologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Dr. Yasodha Natkunam accepting new patients in Pleasanton, CA?
Yes, Dr. Yasodha Natkunam is accepting new patients at this time.
Does Dr. Yasodha Natkunam offer online booking?
Please contact Dr. Natkunam's office at (650) 723-7211 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Dr. Yasodha Natkunam?
Please contact Dr. Natkunam's office at (650) 723-7211 to schedule an appointment.
Where is Dr. Natkunam's office located?
Dr. Natkunam's offices are located in Pleasanton, CA and Stanford, CA.
Which board certifications does Dr. Yasodha Natkunam have?
Dr. Yasodha Natkunam is certified by the American Board of Pathology.
Other Anatomic Pathologist & Clinical Pathologist Near Pleasanton, CA
Anatomic Pathologist & Clinical Pathologist
Accepting patientsAnatomic Pathologist & Clinical Pathologist
Accepting patients
Dermatologist
Accepting patients